Encysive, Revotar deal

Revotar acquired from ENCY rights it did not already hold to bimosiamose, a selectin antagonist to treat psoriasis. ENCY previously held North American rights to topical applications of the compound (see BioCentury, Jan. 12, 2004). ENCY is eligible for royalties on revenues from commercialization or licensing activities related to bimosiamose or follow-on compounds. Also, ENCY will cancel a $3.7 million loan it previously granted Revotar. ...